首页> Genes & development> ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.

ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.

导出 OA

翻译打印收藏纠错

第一作者： Mingchao,Wang

第一单位： Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.;Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.

作者： Mingchao,Wang ^[1] ; Xiaojuan,Ran ^[2] ; Wendy,Leung ^[3] ; Ajinkya,Kawale ^[3] ; Sneha,Saxena ^[3] ; Jian,Ouyang ^[2] ; Parasvi S,Patel ^[3] ; Yuting,Dong ^[3] ; Tao,Yin ^[4] ; Jian,Shu ^[5] ; Robert T,Manguso ^[6] ; Li,Lan ^[7] ; Xiao-Fan,Wang ^[4] ; Michael S,Lawrence ^[6] ; Lee,Zou ^[8]

作者单位： Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.;Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA. ^[1] Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.;Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27708, USA. ^[2] Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA. ^[3] Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27708, USA. ^[4] Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA. ^[5] Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.;Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA. ^[6] Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.;Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA. ^[7] Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA; lee.zou@duke.edu.;Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27708, USA.;Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[8]

关键词 ATR MMR MSI immunotherapy synthetic lethality

医学主题词脑肿瘤(Brain Neoplasms);结直肠肿瘤(Colorectal Neoplasms);免疫疗法(Immunotherapy);DNA(DNA);小鼠(Mice);动物(Animals);肿瘤综合征, 遗传性(Neoplastic Syndromes, Hereditary);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);DNA错配修复(DNA Mismatch Repair)

DOI 10.1101/gad.351084.123

PMID 37932012

发布时间 2024-04-02

基金项目

R01 CA248526/CA/NCI NIH HHS/United States R01 CA249726/CA/NCI NIH HHS/United States R35 CA263934/CA/NCI NIH HHS/United States R50 CA274158/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交